Follow Us:Follow Us on Twitter Like Us on Facebook Follow Us on Google+ Watch videos on our Youtube channel
Cedars-Sinai Medical Center's Women's Heart Program Provides Innovative Diagnostic Test For Microvascular Disease
It is estimated that about two to three million women in the U.S. may suffer from undiagnosed microvascular disease, a dysfunction of the heart’s small arteries that is not being diagnosed using conventional methods such as electrocardiograms, exercise stress tests, echocardiograms and angiograms. As part of its new Women’s Heart Program, Cedars-Sinai Medical Center is the only center on the West Coast providing an innovative, two-step pharmacological diagnostic test aimed at this condition.
Los Angeles - May 1, 2006 - Internationally renowned cardiologist C. Noel Bairey Merz, MD, is hoping that innovative diagnostic tests for microvascular cardiac disease, such as those offered at Cedars- Sinai Medical Center, will help lead researchers to develop more effective ways to treat this disease which occurs nearly four times as often in women as in men.
“Only in recent years have physicians become aware of microvascular disease − a dysfunction of the heart’s small arteries − as a significant problem for women,” explains Bairey Merz, who directs Cedars-Sinai’s new Women’s Heart Program and its Preventive and Rehabilitative Cardiac Center. “Now the challenge is to integrate into medical practice systematic ways to diagnose and treat the condition.”
It is estimated that about two to three million women in the U.S. may suffer from microvascular cardiac disease that is not being diagnosed by conventional detection methods. In light of this, Cedars-Sinai’s Women’s Health Program is focusing its expertise on diagnosing and reducing heart disease through a preventive approach that includes state-of-the-art screening and diagnostic testing.
Microvascular coronary artery disease affects the small arteries found throughout the heart, reducing their ability to maintain the oxygen needed by the heart muscle to function properly. The usual tests to diagnose coronary heart disease – electrocardiogram (EKG), exercise stress test, echocardiogram and angiogram – test for dysfunction in the large arteries. Until recently, there was not an accurate diagnostic test for disease in the small arteries.
A new, pharmacological stress test for microvascular disease − an acetylcholine endothelial function and adensosine coronary flow reserve test − is now available at Cedars-Sinai’s Cardiovascular Interventional Center and promises to “greatly enhance our ability to diagnose and treat women with ischemic heart disease,” says Bairey Merz.
During the two-step test, the drug adenosine, which normally causes the small vessels of the heart to dilate, is injected into one of the coronary arteries and the amount of blood flow is measured. Next, the drug acetylcholine, which normally causes dilation in the large arteries, is injected and the amount of blood flow is again measured. If either test shows decreased blood flow to the heart muscle, a diagnosis of disease can be made in women with evidence of insufficient blood flow to the heart muscle and open coronary arteries. Medical therapy is then directed at the specific problem.
Another new test to help researchers better diagnose microvascular coronary disease is cardiac MRI which is available at Cedars-Sinai’s S. Mark Taper Foundation Imaging Center. This test can show poor blood supply to the inside layer of the heart muscle.
Accurately diagnosing microvascular cardiac disease is the first step, Bairey Merz says, but continued research is needed to identify the best course of treatment. “Currently, we have several small studies that indicate the efficacy of different treatments but we don’t have any good, large randomized trials yet to look at how treating this condition may lead to reductions in heart attack, stroke and heart failure. The bottom line is that we need to explore this further, so we can develop therapies that are specific to this type of disease.”